Immunogenic lipid markers of atherosclerosis in type 2 diabetic patients on program haemodialysis
- Authors: Archakova TV1, Nedosugova LV1, Nikitina NA2, Melnichenko AA2, Sobenin IA2
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Healht of Russia
- National Medical Research Center of Cardiology, Ministry of Healht of Russia
- Issue: Vol 90, No 10 (2018)
- Pages: 40-45
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32850
- DOI: https://doi.org/10.26442/terarkh201890104-45
- ID: 32850
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
T V Archakova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Healht of Russia
Email: tat.archackova2010@yandex.ru
аспирант каф. эндокринологии Первого МГМУ им. И.М. Сеченова Moscow, Russia
L V Nedosugova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Healht of Russia
Email: profmila@mail.ru
проф. каф. эндокринологии Первого МГМУ им. И.М. Сеченова Moscow, Russia
N A Nikitina
National Medical Research Center of Cardiology, Ministry of Healht of Russia
Email: nikitinanadyaa@mail.ru
к.б.н., с.н.с. лаб. биохимии свободнорадикальных процессоов Института клинической кардиологии им. А.Л. Мясникова НМИЦ кардиологии Moscow, Russia
A A Melnichenko
National Medical Research Center of Cardiology, Ministry of Healht of Russia
Email: sasha.melnichenko@gmail.ru
д.б.н., в.н.с. лаб. медицинской генетики Института клинической кардиологии им. А.Л. Мясникова НМИЦ кардиологии Moscow, Russia
I A Sobenin
National Medical Research Center of Cardiology, Ministry of Healht of Russia
Email: igor.sobenin@gmail.ru
д.м.н., руководитель лаб. медицинской генетики Института клинической кардиологии им. А.Л. Мясникова НМИЦ кардиологии Moscow, Russia
References
- Дедов И.И., Мельниченко Г.А., редакторы. Эндокринология. Клинические рекомендации. 2-е изд., исправленное и дополненное Москва: ГЭОТАР-Медиа; 2007. 318 с.
- Зубкова С.Т. Факторы риска атеросклероза у больных с сахарным диабетом. Здоровье Украины. 2013;(2):24-25.
- Souvik S, Stephen M. Risk Factors for Progression of Aortic Atheroma in Stroke and Transient Ischemic Attack Patients. Stroke. 2002;33:930-935. doi: 10.1161/01.STR.0000014210.99337.D7
- Отс М., Пехтер У. Преждевременный атеросклероз при хронической почечной недостаточности. Нефрология и диализ. 2002;4(3):210-213.
- Lehto S, Niskanen L, Ronnemaa T, Laakso M. Medial artery calcification in non insulin dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16:978-983. doi: 10.1161/01.ATV.16.8.978
- Kannel W.B, Larson M. Long - term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology. 1993;(82):137-152. doi: 10.1159/000175864
- Griffith R.L, Virella G.T, Stevenson H.C, Lopes-Virella M.F. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988;168(3):1041-1059. doi: 10.1084/jem.168.3.1041
- Zakiev E.R, Sobenin I.A, Sukhorukov V.N, Myasoedova V.A, Ivanova E.A, Orekhov A.N. Carbohydrate composition of circulating multiple - modified low - density lipoprotein. Vasc Health Risk Manag. 2016;12:379-385. doi: 10.2147/vhrm.s112948
- Zakiev E.R, Sukhorukov V.N, Melnichenko A.A, Sobenin I.A, Ivanova E.A, Orekhov A.N. Lipid composition of circulating multiple - modified low density lipoprotein. Lipids Health Dis. 2016;15:134. doi: 10.1186/s12944-016-0308-2
- Sobenin I.A, Tertov V.V, Orekhov A.N. Atherogenic modified LDL in diabetes. Diabetes. 1996;45(3):S35-S39. doi: 10.2337/diab.45.3.s35
- Palinski W, Rosenfeld M.E, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Nat Acad Sci U. S. A. 1989;86(4):1372-1376. doi: 10.1073/pnas.86.4.1372
- Piarulli F, Lapolla A, Sartore G. Autoantibodies Against Oxidized LDLs and Atherosclerosis in Type 2 Diabetes. Diabetes Care. 2005;28:653-657. doi: 10.2337/diacare.28.3.653
- Orekhov A.N, Bobryshev Y.V, Sobenin I.A, Melnichenko A.A, Chistiakov D.A. Modified low density lipoprotein and lipoprotein - containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. Int J Mol Sci. 2014;15:12807-12841. doi: 10.3390/ijms150712807
- Virella G, Lopes-Virella M.F. The role of the immune system in the pathogenesis of diabetic complications. Front Endocrinol (Lausanne). 2014;5:126. doi: 10.3389/fendo.2014.00126
- Hunt K.J, Baker N, Cleary P, Backlund J.Y, Lyons T, Jenkins A, Virella G, Lopes-Virella M.F. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013;231:315-322. doi: 10.1016/j.atherosclerosis.2013.09.027
- Ketelhuth D.F, Hansson G.K. Modulation of autoimmunity and atherosclerosis - common targets and promising translational approaches against disease. Circ J. 2015;79(5):924-933. doi: 10.1253/circj.cj-15-0167
- Lovre D, Shah S, Sihota A, Fonseca V.A. Managing diabetes and cardiovascular risk in chronic kidney disease patients. Endocrinol Metab Clin North Am. 2018;47:237-257. doi: 10.1016/j.ecl.2017.10.006
- Winocour P.H. Diabetes and chronic kidney disease: an increasingly common multi - morbid disease in need of a paradigm shift in care. Diabet Med. 2018;35:300-305. doi: 10.1111/dme.13564
- Burut D.F, Karim Y. The role of immune complexes in atherogenesis. Angiology. 2010;61(7):679-689. doi: 10.1177/0003319710366124
- Virella G, Lopes-Virella M.F. The pathogenic role of the adaptive immune response to modified LDL in diabetes. Front Endocrinol (Lausanne). 2012;3:76. doi: 10.3389/fendo.2012.00076
- Lindgren F.T. Preparative ultracentrifugal laboratory procedures and suggestions for lipoprotein analysis. In: Perkins E.D, ed. Analysis of lipids and lipoproteins. New York: American Oil Chemical Society; 1975. P. 205-224.
- Tertov V.V, Sobenin I.A, Tonevitsky A.G, Orekhov A.N, Smirnov V.N. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun. 1990;167(3):1122-1127. doi: 10.1016/0006-291x(90)90639-5
- Sobenin I.A, Tertov V.V, Koschinsky T, Bunting C.E, Slavina E.S, Dedov I.I, Orekhov A.N. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis. 1993;100:41-54. doi: 10.1016/0021-9150(93)90066-4
- Campbell D.J, Neal B.C, Chalmers J.P, Colman S.A, Jenkins A.J, Kemp B.E, et al. Low - density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. Eur J Cardiovasc Prev Rehabil. 2007;14(3):413-418. doi: 10.1097/hjr.0b013e328010f275
- Tertov V.V, Mukhin D.N, Mikhallenko I.A. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun. 1989;162:206-211. doi: 10.1016/0006-291x(89)91982-7
- Lopes-Virella M.F, Klein R.L, Lyons T.J, Stevenson H.C, Witztum J.L. Glycosylation of low - density lipoprotein enhances cholesteryl ester synthesis in human monocytederived macrophages. Diabetes. 1988;37(5):550-557. doi: 10.2337/diabetes.37.5.550
- Tanaka M, Abe Y, Furukado S, Miwa K, Sakaguchi M, Sakoda S, Kitagawa K. Chronic Kidney Disease and Carotid Atherosclerosis. Stroke Cerebrovasc Dis. 2012;21(1):47-51. doi: 10.1016/j.jstrokecerebrovasdis.2010.03.018
- Dahlen G.H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-126. doi: 10.1016/0021-9150(94)90106-6
- Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77-82. doi: 10.2337/diaclin.26.2.77
- Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A. Impact of carotid atherosclerosis on long - term mortality in chronic hemodialysis patients. Kidney Int. 2003;64(4):1472-1479. doi: 10.1046/j.1523-1755.2003.00205.x
- Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Nat Acad Sci. 1994;91(20):9441-9445. doi: 10.1073/pnas.91.20.9441
- Klimov A.N, Denisenko A.D, Popov A.V. Lipoproteinantibody immune complexes their catabolism and role in foam cell formation. Atherosclerosis. 1985;58(1-3):1-15. doi: 10.1016/0021-9150(85)90051-6
- Бабинцева Я.Д., Сергеева А.М., Карагодин В.П., Орехов А.Н. Атерогенез у человека - клинические аспекты циркулирующих иммунных комплексов. Клиническая медицина. 2016;94(5):325-332. doi: 10.18821/0023-2149-2016-94-5-325-332
- Gonen B, Fallon J.J, Baker S.A. Immunogenicity of malondialdehyde - modified low density lipoproteins: studies with monoclonal antibodies. Atherosclerosis. 1987;65:265-272. doi: 10.1016/0021-9150(87)90042-6
- Numano F, Tanaka A, Makita T, Kishi Y. Glycated lipoprotein and atherosclerosis. Ann NY Acad Sci. 1997;811:100-114. doi: 10.1111/j. 1749-6632.1997.tb51993.x
- Galle J, Wanner С. Modification of Lipoproteins in Uremia: Oxidation, Glycation and Carbamoylation. Mineral Electrol Metab. 1999;25:263-268.